These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32648839)

  • 1. Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect.
    Kras P; Talkowski K; Grabarek BO; Skalska-Dziobek N; Boroń D; Oplawski M
    Curr Pharm Biotechnol; 2021; 22(5):697-705. PubMed ID: 32648839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the Differences in the Expression of mRNAs and miRNAs Associated with Drug Resistance in Endometrial Cancer Cells Treated with Salinomycin.
    Januszyk P; Januszyk K; Wierzbik-Strońska M; Boroń D; Grabarek B
    Curr Pharm Biotechnol; 2021; 22(4):541-548. PubMed ID: 32598254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salinomycin Modulates the Expression of mRNAs and miRNAs Related to Stemness in Endometrial Cancer.
    Talkowski K; Kiełbasiński K; Peszek W; Grabarek BO; Boroń D; Oplawski M
    Curr Pharm Biotechnol; 2021; 22(2):317-326. PubMed ID: 32564748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line.
    Kiełbasiński K; Peszek W; Grabarek BO; Boroń D; Wierzbik-Strońska M; Oplawski M
    Curr Pharm Biotechnol; 2020; 21(12):1269-1277. PubMed ID: 32400328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
    Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
    BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer.
    Oplawski M; Dziobek K; Zmarzły N; Grabarek B; Halski T; Januszyk P; Kuś-Kierach A; Adwent I; Dąbruś D; Kiełbasiński K; Boroń D
    Curr Pharm Biotechnol; 2019; 20(12):1004-1010. PubMed ID: 31333122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of Salinomycin on the Expression Profile of mRNAs Encoding Selected Caspases and MiRNAs Regulating their Expression in Endometrial Cancer Cell Line.
    Januszyk K; Januszyk P; Grabarek BO; Boroñ D; Oplawski M
    Curr Pharm Biotechnol; 2020; 21(14):1505-1515. PubMed ID: 32407273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Glucose Promotes Epithelial-Mesenchymal Transition of Uterus Endometrial Cancer Cells by Increasing ER/GLUT4-Mediated VEGF Secretion.
    Gu CJ; Xie F; Zhang B; Yang HL; Cheng J; He YY; Zhu XY; Li DJ; Li MQ
    Cell Physiol Biochem; 2018; 50(2):706-720. PubMed ID: 30308493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
    Lohela M; Bry M; Tammela T; Alitalo K
    Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer.
    Dziobek K; Opławski M; Grabarek BO; Zmarzły N; Tomala B; Halski T; Leśniak E; Januszyk K; Brus R; Kiełbasiński R; Boroń D
    Curr Pharm Biotechnol; 2019; 20(11):955-963. PubMed ID: 31322068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphangiogenic growth factors, receptors and therapies.
    Lohela M; Saaristo A; Veikkola T; Alitalo K
    Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profile and proliferative responses of rat lymphatic endothelial cells in culture.
    Whitehurst B; Eversgerd C; Flister M; Bivens CM; Pickett B; Zawieja DC; Ran S
    Lymphat Res Biol; 2006; 4(3):119-42. PubMed ID: 17034293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.
    Hwang-Bo J; Bae MG; Park JH; Chung IS
    BMC Cancer; 2018 Jul; 18(1):714. PubMed ID: 29976150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
    Girling JE; Donoghue JF; Lederman FL; Cann LM; Achen MG; Stacker SA; Rogers PA
    Reprod Biol Endocrinol; 2010 Jul; 8():84. PubMed ID: 20615255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
    Underiner TL; Ruggeri B; Gingrich DE
    Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.